glp-1 drugs cancer Linked to Dramatically Lower Death Rates in Colon Patients GLP-1 drugs may have a

The future oral GLP-1 receptor agonists, incretin dual agonists, triple agonists, and other new oral metabolic products will become popular only if they prove themselves capable of producing sustained results in obesity disease, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risks, and metabolic syndromes through their effectiveness and safety

E.UsuelliV.PastoreI.LazzaroniE.et al (2022)

So they appear to stand to benefit quite a lot

doi: 10.1038/ijo.2011.158 240 BlundellJFinlaysonGAxelsenMFlintAGibbonsCKvistTet al

Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines

Mendes FF, Carvalho LIM, Lopes MB